PortfoliosLab logo
PACB vs. CRSP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between PACB and CRSP is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.4

Performance

PACB vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

-100.00%0.00%100.00%200.00%300.00%NovemberDecember2025FebruaryMarchApril
-87.40%
171.61%
PACB
CRSP

Key characteristics

Sharpe Ratio

PACB:

-0.23

CRSP:

-0.59

Sortino Ratio

PACB:

0.43

CRSP:

-0.68

Omega Ratio

PACB:

1.04

CRSP:

0.93

Calmar Ratio

PACB:

-0.26

CRSP:

-0.38

Martin Ratio

PACB:

-0.79

CRSP:

-1.14

Ulcer Index

PACB:

32.58%

CRSP:

28.09%

Daily Std Dev

PACB:

110.72%

CRSP:

54.80%

Max Drawdown

PACB:

-97.87%

CRSP:

-85.11%

Current Drawdown

PACB:

-97.87%

CRSP:

-81.78%

Fundamentals

Market Cap

PACB:

$348.49M

CRSP:

$3.38B

EPS

PACB:

-$1.55

CRSP:

-$4.34

PEG Ratio

PACB:

-0.17

CRSP:

-0.21

PS Ratio

PACB:

2.26

CRSP:

90.52

PB Ratio

PACB:

0.69

CRSP:

1.75

Total Revenue (TTM)

PACB:

$115.20M

CRSP:

$36.12M

Gross Profit (TTM)

PACB:

$26.00M

CRSP:

-$32.01M

EBITDA (TTM)

PACB:

-$319.24M

CRSP:

-$311.55M

Returns By Period

In the year-to-date period, PACB achieves a -40.44% return, which is significantly lower than CRSP's -2.77% return.


PACB

YTD

-40.44%

1M

-14.17%

6M

-38.42%

1Y

-21.01%

5Y*

-19.52%

10Y*

-15.11%

CRSP

YTD

-2.77%

1M

-2.32%

6M

-19.19%

1Y

-28.77%

5Y*

-6.67%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

PACB vs. CRSP — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PACB
The Risk-Adjusted Performance Rank of PACB is 4141
Overall Rank
The Sharpe Ratio Rank of PACB is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of PACB is 5050
Sortino Ratio Rank
The Omega Ratio Rank of PACB is 4747
Omega Ratio Rank
The Calmar Ratio Rank of PACB is 3535
Calmar Ratio Rank
The Martin Ratio Rank of PACB is 3434
Martin Ratio Rank

CRSP
The Risk-Adjusted Performance Rank of CRSP is 2222
Overall Rank
The Sharpe Ratio Rank of CRSP is 1919
Sharpe Ratio Rank
The Sortino Ratio Rank of CRSP is 1919
Sortino Ratio Rank
The Omega Ratio Rank of CRSP is 2222
Omega Ratio Rank
The Calmar Ratio Rank of CRSP is 2828
Calmar Ratio Rank
The Martin Ratio Rank of CRSP is 2222
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

PACB vs. CRSP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for PACB, currently valued at -0.23, compared to the broader market-2.00-1.000.001.002.003.00
PACB: -0.23
CRSP: -0.59
The chart of Sortino ratio for PACB, currently valued at 0.43, compared to the broader market-6.00-4.00-2.000.002.004.00
PACB: 0.43
CRSP: -0.68
The chart of Omega ratio for PACB, currently valued at 1.04, compared to the broader market0.501.001.502.00
PACB: 1.04
CRSP: 0.93
The chart of Calmar ratio for PACB, currently valued at -0.26, compared to the broader market0.001.002.003.004.005.00
PACB: -0.26
CRSP: -0.38
The chart of Martin ratio for PACB, currently valued at -0.79, compared to the broader market-5.000.005.0010.0015.0020.00
PACB: -0.79
CRSP: -1.14

The current PACB Sharpe Ratio is -0.23, which is higher than the CRSP Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of PACB and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.50NovemberDecember2025FebruaryMarchApril
-0.23
-0.59
PACB
CRSP

Dividends

PACB vs. CRSP - Dividend Comparison

Neither PACB nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

PACB vs. CRSP - Drawdown Comparison

The maximum PACB drawdown since its inception was -97.87%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for PACB and CRSP. For additional features, visit the drawdowns tool.


-95.00%-90.00%-85.00%-80.00%-75.00%NovemberDecember2025FebruaryMarchApril
-97.87%
-81.78%
PACB
CRSP

Volatility

PACB vs. CRSP - Volatility Comparison

Pacific Biosciences of California, Inc. (PACB) has a higher volatility of 30.98% compared to CRISPR Therapeutics AG (CRSP) at 22.51%. This indicates that PACB's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%35.00%40.00%NovemberDecember2025FebruaryMarchApril
30.98%
22.51%
PACB
CRSP

Financials

PACB vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Pacific Biosciences of California, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items